|
Hematology/Oncology Research Studies: Open for Enrollment | Date: 01/26/21 |
|---|
| NCT#/Phase: | NCT02176967 Phase 3 |
|---|---|
| IRB#: | 2014-051 |
| Description: | This Phase III trial in patients with non-high-risk neuroblastoma or ganglioneuroblastoma continues a response and biology based treatment approach utilized on prior studies, but patient subgroups will be further refined using histologic and genomic criteria, and therapy modified accordingly. Patients will be assigned to the appropriate treatment group based on the patient’s age, tumor stage and biologic features of International Neuroblastoma Pathology Classification (INPC) histology and genomic features (MCYN status, DNA ploidy and genomic profile). |
| Inclusion: | |
| Enrollment Status: | Open for enrollment |
| Sponsor: | COG |
| Principal Investigator(s): | Carla Golden, MD |
| Contact(s): | Sheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611) COG CRA Office (510-428-3885 x8334) |
| Study Link: | https://clinicaltrials.gov/ct2/show/NCT02176967 |